Tags

Type your tag names separated by a space and hit enter

Clinical Review Report: Sucroferric Oxyhydroxide (Velphoro): (Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis

Abstract
The objective of this report was to perform a systematic review of the beneficial and harmful effects of sucroferric oxyhydroxide to control serum phosphorus levels in adult patients with end-stage renal disease on dialysis.

Publisher

Canadian Agency for Drugs and Technologies in Health
Ottawa (ON)

Language

eng

PubMed ID

31206292

Citation

Clinical Review Report: Sucroferric Oxyhydroxide (Velphoro): (Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis. Canadian Agency for Drugs and Technologies in Health, 2019, Ottawa (ON).
Clinical Review Report: Sucroferric Oxyhydroxide (Velphoro): (Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
(2019). In Clinical Review Report: Sucroferric Oxyhydroxide (Velphoro): (Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
Clinical Review Report: Sucroferric Oxyhydroxide (Velphoro): (Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
* Article titles in AMA citation format should be in sentence-case
TY - BOOK T1 - Clinical Review Report: Sucroferric Oxyhydroxide (Velphoro): (Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis Y1 - 2019/02// PY - 2019/6/18/pubmed PY - 2019/6/18/medline PY - 2019/6/18/entrez N2 - The objective of this report was to perform a systematic review of the beneficial and harmful effects of sucroferric oxyhydroxide to control serum phosphorus levels in adult patients with end-stage renal disease on dialysis. PB - Canadian Agency for Drugs and Technologies in Health CY - Ottawa (ON) UR - https://www.unboundmedicine.com/medline/citation/31206292/Clinical_Review_Report:_Sucroferric_Oxyhydroxide_(Velphoro):_(Vifor_Fresenius_Medical_Care_Renal_Pharma_Ltd.):_Indication:_For_the_control_of_serum_phosphorus_levels_in_adult_patients_with_end-stage_renal_disease_on_dialysis L2 - https://www.ncbi.nlm.nih.gov/books/NBK542396 DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows